KLK3 and neoplasm: The NCCN guideline state that favorable intermediate-risk men with a life expectancy >10 years may be considered for AS, particularly in men with a low percentage of Gleason 4 pattern, low tumor volume, low PSA density, and/or low genomic risk (from tissue-based tumor molecular analysis) [4].